CP and chronic myelogenous leukemia, BCR-ABL1 positive: We hypothesized that this was due to pre-existing immunological memory against the former class of antigens (from patients' own prior exposure to autologous CML) and that the expression of this latter class of ‘late' antigens would be higher in K562 cell line, from which the vaccine product was derived, than in primary CML-CP.